PharmaEngine (4162) — Capital Reinvestment Ratio
PharmaEngine (4162) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow (NT$53.01 Million) in capital expenditures (NT$115.00K). Check PharmaEngine tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
PharmaEngine Capital Reinvestment Ratio (2011–2024)
This chart tracks PharmaEngine's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see PharmaEngine (4162) cash conversion ratio.
Annual Capital Reinvestment Ratio for PharmaEngine (2011–2024)
Year-by-year Capital Reinvestment Ratio for PharmaEngine from 2011 to 2024. See PharmaEngine free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | NT$456.73 Million | NT$1.42 Million | ▼ -16.9% |
| 2023 | 0.00x | NT$256.97 Million | NT$958.00K | ▼ -80.9% |
| 2022 | 0.02x | NT$202.01 Million | NT$3.94 Million | ▲ +7825.9% |
| 2021 | 0.00x | NT$929.67 Million | NT$229.00K | ▼ -97.4% |
| 2020 | 0.01x | NT$64.77 Million | NT$608.00K | ▼ -27.4% |
| 2019 | 0.01x | NT$16.08 Million | NT$208.00K | ▲ +1790.4% |
| 2018 | 0.00x | NT$745.23 Million | NT$510.00K | ▼ -48.0% |
| 2016 | 0.00x | NT$870.38 Million | NT$1.15 Million | ▼ -95.0% |
| 2015 | 0.03x | NT$447.99 Million | NT$11.80 Million | ▲ +3535.1% |
| 2014 | 0.00x | NT$131.09 Million | NT$95.00K | ▼ -40.1% |
| 2012 | 0.00x | NT$68.64 Million | NT$83.00K | ▼ -58.7% |
| 2011 | 0.00x | NT$275.49 Million | NT$806.00K | — |